TACSTD2 and triple-negative breast carcinoma: For example, Omori et al. hypothesised in their study [70] that neoadjuvant therapies can lead to a change in Trop2 expression in certain lung cancer patients, while research in triple-negative breast cancers showed no significant change in Trop2 expression in non-pretreated vs. pretreated tumours [71].